Crossmark

The CetuxIMAX study: a population pharmacokinetic approach to modelling the pharmacokinetics and pharmacodynamics relationships of Cetuximab in patients with head and neck cancer

Crossref DOI link: https://doi.org/10.1007/s00280-026-04892-y

Published Online: 2026-04-29

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Deschamps, Anthéa

Marin, Clémence

Gerbault, Quentin

Toullec, Clémence

Clatot, Florian

Bernadach, Maureen

Fayette, Jérôme

Daste, Amaury

Ceruse, Philippe

Burgy, Mickael

Champetier, Cédric

Abdeddaim, Cyril

Saada-Bouzid, Esma

Tchiknavorian, Xavier

Zanetta, Sylvie

Auquier, Pascal

Ciccolini, Joseph

Salas, Sébastien
Funding

Funding for this research was provided by:

Merck
License Information

Text and Data Mining valid from 2026-04-29

Version of Record valid from 2026-04-29
More Information

Article History

Received: 12 January 2026

Accepted: 7 April 2026

First Online: 29 April 2026

Declarations

:

: The authors declare no conflict of interest in relation with the present study.

Document is current

Any future updates will be listed below